Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic, Safety, and Immunogenicity Comparative Study of EnliTuo Before and After Technology Change in Healthy Male Volunteers
NCT07246291Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoint: Area Under the Curve from Time Zero to Infinity at 28 days. Started Nov 2025; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07246291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246291.